Insmed Incorporated

Insmed Incorporated

INSM·NASDAQ

$103.86

+0.13%
HealthcareBiotechnology

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

At a Glance

Live Snapshot
Market Cap$22.51B
EPS-6.4100
P/E Ratio-16.20
Earnings Date08/06/2026

insm

Additional Paid-In Capital

Last Annual Value

6.37B

3-Year CAGR

32%

5-Year CAGR

25%

10-Year CAGR

22%

Insmed Incorporated

Insmed Incorporated Competitors Analysis of Additional Paid-In Capital

INSM · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
6.37B
27.0%19.0%21.4% 
RMD logo
ResMed Inc.
NYSE:RMD
2.03B
4.7%4.6%4.6%
6.71B
1.1%N/AN/A
HUM logo
Humana Inc.
NYSE:HUM
3.60B
2.5%3.2%3.5%
5.58B
1.2%0.9%-4.8%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
12.76B
3.2%2.7%36.0%
Insmed Incorporated

Insmed Incorporated Fair Value Envelope

INSM · NASDAQ

Our analysis suggests that INSM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $103.86, this represents a potential HIDDEN relative to our calculated worth for Insmed Incorporated.

Intrinsic Value
Current Price: $103.86